Orn-0829 hydrate
As of the edition of 20 October 2026, Orn-0829 hydrate is a drug: marketed, first approved in 2025 (JP); acts on HCRTR1 and HCRTR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Unknown
- Brand name
- Vorzzz
- First approved
- 25 August 2025 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Taisho Pharmaceutical
- Registered trials
- 15, 0 stopped early
- Disease areas
- Mental health; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 11 | 11 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 15 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Taisho Pharmaceutical | Applicant and Lead sponsor of trials | 2015 to now |